Curis Salute del bilancio
Criteri Salute finanziaria verificati 5/6
Curis ha un patrimonio netto totale di $5.5M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $20.0M e $14.5M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
US$0
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | US$5.06m |
| Patrimonio netto | US$5.46m |
| Totale passività | US$14.50m |
| Totale attività | US$19.97m |
Aggiornamenti recenti sulla salute finanziaria
We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate
Nov 03
We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely
Aug 05Recent updates
CRIS: Expanded Share Authorization And Elevated Future P/E Will Support Upside
Analysts have raised the price target on Curis to $5.00 from $5.00, citing updated assumptions around discount rates, slightly less severe expected revenue contraction, lower profit margins, and a higher future P/E multiple. Analyst Commentary Recent Street research on peer names in the broader consumer space highlights how quickly sentiment can shift when expectations around earnings power, tariff exposure, and valuation multiples come under scrutiny.CRIS: Expanded Capital Base And Elevated Future P/E Will Support Upside
Analysts have adjusted their price target on Curis to $5.00 from $5.00, citing slightly lower discount rate and revenue decline assumptions, along with a higher future P/E multiple, as key drivers of the updated view. Analyst Commentary Bearish analysts looking at Curis are focusing on how the current valuation lines up with execution risk and the assumptions baked into the updated price target.CRIS: Expanded Capital Base And Rich Future P/E Will Support Upside
The analyst price target for Curis has been adjusted from $5 to $5.00. Analysts cite a lower discount rate, a shift to expectations of a 15.61% revenue decline, and a significantly higher assumed future P/E multiple as the main factors behind this revision.
CRIS: Maintained US$14 Fair Value Will Depend On Execution Risk
Analysts have maintained their $14.00 price target on Curis while adjusting key inputs, including a slightly lower discount rate, a revised profit margin outlook, and a higher future P/E assumption to reflect updated views on execution risk and valuation support. Analyst Commentary Analysts covering Curis are focusing less on big headline calls and more on how the updated assumptions behind the $14.00 price target line up with execution risk, profitability, and valuation support.CRIS: Expanded Capital Base And Financing Structure Will Support Long-Term Upside
Narrative update on Curis The analyst price target for Curis has been lifted by $7, with analysts pointing to a slightly lower discount rate, modestly higher revenue growth expectations and a somewhat richer future P/E assumption as key drivers of the change. Analyst Commentary Recent Street research around comparable names highlights how quickly sentiment can swing when execution, growth visibility, or valuation do not line up cleanly.CRIS: Maintained US$14 Fair Value Will Rely On Clinical Progress
Analysts have kept their price target for Curis steady at US$14.00. The updated view reflects slightly lower discount rate and profit margin assumptions, which are offset by a modestly reduced future P/E multiple.CRIS: Frontline AML Data And Insider-Backed Financing Will Support Long-Term Upside
Analysts have lifted their price target on Curis to $5.00 from $5.00, citing updated assumptions around higher projected revenue growth and slightly stronger long-term profit margins, partially tempered by a higher discount rate and a lower future P/E multiple. Analyst Commentary Recent Street research on other consumer names highlights several themes that cautious investors are watching closely and that can be relevant when you think about Curis as well.CRIS: Higher Future P/E And Clinical Progress Will Support Long Term Earnings
Analysts have raised their price target on Curis to $14.00, a change they link to updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple. Analyst Commentary Analysts are applying a similar playbook across several consumer names, and that context helps explain the recent price target move on Curis.Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge
Jan 04CRIS: Frontline AML Data Will Drive Long-Term Upside Despite Heightened Risk
Analysts have cut their price target on Curis from $12.00 to $5.00 as they increase the assumed discount rate, while also lifting revenue growth expectations and lowering future valuation multiples. This reflects a more cautious yet still constructive outlook on the company’s long-term earnings power.CRIS: Reduced Risk Profile Will Support Long Term Earnings Recovery
Analysts have nudged their price target on Curis modestly higher to $14.00, citing slightly lower perceived risk and a marginally cheaper future earnings multiple. Together, these factors support a cautiously more constructive long term outlook.CRIS: Cost Efficiencies Will Drive Earnings Recovery Despite Macro Pressures
Curis's analyst price target has been raised modestly, with analysts citing improved profit margin projections and a better cost outlook as reasons for the updated valuation of $14.00 per share. Analyst Commentary Analysts recently updated their perspectives on Curis in light of the company’s latest performance and forward-looking guidance.Curis, Inc. (NASDAQ:CRIS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Nov 20CRIS: Cost-Saving Initiatives Will Support Stronger Revenue Expansion Into 2026
Curis's analyst price target has been reduced from $16.33 to $14.00. This adjustment reflects analysts' concerns over softer profit margins, even with stronger revenue growth projections and an increased discount rate.Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target
Aug 08
FDA And EMA Will Accelerate Emavusertib Clinical Trials
Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space.Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)
Apr 02Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30%
Apr 01Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Dec 29Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Nov 14Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Aug 07Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
Aug 05Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Apr 03Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry
Dec 26We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate
Nov 03We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely
Aug 05Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?
Apr 19Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?
Jan 02Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( { CRIS di $6.9M ) non coprono le sue passività a breve termine ( $14.1M ).
Passività a lungo termine: Le attività a breve termine di CRIS ( $6.9M ) superano le sue passività a lungo termine ( $428.0K ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: CRIS è esente da debiti.
Riduzione del debito: CRIS non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 45.2%.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: CRIS ha una liquidità sufficiente per 2 mesi in base all'ultimo reportfree cash flow, ma da allora ha raccolto ulteriori capitali.
Previsione Cash Runway: Si prevede che CRIS disponga di liquidità sufficiente per 2 mesi in base al flusso di cassa libero estimates, ma da allora ha raccolto capitale aggiuntivo.
Scoprire le aziende sane
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/01 02:28 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Curis, Inc. è coperta da 16 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Brian Skorney | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Justin Walsh | B. Riley Securities, Inc. |